EF Hutton Maintains Buy on VolitionRX, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tim Moore has maintained a Buy rating on VolitionRX (AMEX:VNRX) with a price target of $4.5.
May 14, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Tim Moore reaffirmed a Buy rating on VolitionRX, with a steady price target of $4.5, indicating a positive outlook on the stock.
The maintenance of a Buy rating and a specific price target by a reputable analyst like Tim Moore suggests a strong conviction in the stock's potential. This endorsement is likely to instill confidence among investors, potentially driving up the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100